BiotechTube

AGN-151607 + Placebo

Phase 2Completed
1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Post-Operative Atrial Fibrillation

Conditions

Post-Operative Atrial Fibrillation

Trial Timeline

Mar 1, 2019 → Mar 6, 2023

NCT ID
NCT03779841

About AGN-151607 + Placebo

AGN-151607 + Placebo is a phase 2 stage product being developed by AbbVie for Post-Operative Atrial Fibrillation. The current trial status is completed. This product is registered under clinical trial identifier NCT03779841. Target conditions include Post-Operative Atrial Fibrillation.

What happened to similar drugs?

4 of 12 similar drugs in Post-Operative Atrial Fibrillation were approved

Approved (4) Terminated (0) Active (8)
✅Sugammadex + Neostigmine + Atropine + Rocuronium + Fentanyl + Propofol + SevofluraneMerckApproved
✅granisetron + granisetronRocheApproved
✅Parecoxib SodiumPfizerApproved
✅RopivacaineLundbeckApproved
🔄Test naproxen sodium tablet + Commercial naproxen sodium tablet + Commercial naproxen sodium liquid gels capsule + Placebo tabletJohnson & JohnsonPhase 3
🔄Test acetaminophen + Commercial acetaminophen + Commercial ibuprofen + PlaceboJohnson & JohnsonPhase 3
🔄Comparator: MK0517 + Comparator: ondansetronMerckPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03779841Phase 2Completed

Competing Products

18 competing products in Post-Operative Atrial Fibrillation

See all competitors
ProductCompanyStageHype Score
QutenzaAstellas PharmaPre-clinical
26
Test naproxen sodium tablet + Commercial naproxen sodium tablet + Commercial naproxen sodium liquid gels capsule + Placebo tabletJohnson & JohnsonPhase 3
40
Test acetaminophen + Commercial acetaminophen + Commercial ibuprofen + PlaceboJohnson & JohnsonPhase 3
40
Paracetamol injection + Normal Saline injection + Morhpine PCAJiangsu Hengrui MedicinePhase 2/3
38
Comparator: MK0517 + Comparator: ondansetronMerckPhase 3
40
Sugammadex + Neostigmine + Atropine + Rocuronium + Fentanyl + Propofol + SevofluraneMerckApproved
39
Aprepitant + Placebo to Aprepitant + Ondansetron + Placebo to match ondansetronMerckPhase 2
35
granisetron + granisetronRocheApproved
43
Parecoxib SodiumPfizerApproved
43
lyricaPfizerPhase 3
40
Placebo + Pregabalin + PregabalinPfizerPhase 1
29
Methylnaltrexone + PlaceboPfizerPhase 3
40
HSK16149 capsule + PlaceboHaisco Pharmaceutical GroupPhase 2
35
RopivacaineLundbeckApproved
40
Bupivacaine HCI without epinephrine + HTX-011Heron TherapeuticsPhase 2
25
Sufentanil NanoTab PCA System/15 mcg + morphine IV PCATalpheraPhase 3
30
Sufentanil NanoTab PCA System/15 mcg + Placebo Sufentanil NanoTab PCA SystemTalpheraPhase 3
30
Sufentanil Tablet 30 mcg + Placebo TabletTalpheraPhase 3
30